Erste Ergebnisse zur multizentrischen, randomisierten, kontrollierten Brustkrebs-Diagnostikstudie ToSyMa

• Literatur

• 1 Sung H, Ferlay J, Siegel RL. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71: 209-249
• 2 Lauby-Secretan B, Scoccianti C, Loomis D. et al. Breast Cancer Screening – Viewpoint of the IARC Working Group. N Engl J Med 2015; 372: 2353-2358
• 3 Holland R on behalf of the European Reference Organisation for Quality Assured Breast Screening and Diagnostic Services. EUREF Certification Visit of the National Reference Centers for Mammography in Germany. 2018
• 4 Trocchi P, Kuss O, Kääb-Sanyal V. et al. Trends in surgical treatment for breast cancer in Germany after the implementation of the mammography screening program. Eur J Epidemiol 2019; 34: 1143-1150
• 5 Braun B, Khil L, Tio J. et al. Differences in breast cancer characteristics by mammography screening participation or non-participation – a retrospective observational study. Dtsch Arztebl Int 2018; 115: 520-527
• 6 Khil L, Heidrich J, Wellmann I. et al. Incidence of advanced-stage breast cancer in regular participants of a mammography screening program: a prospective register-based study. BMC Cancer 2020; 20: 174-182
• 7 Waldmann A, Hübner J, Katalinic A. Trends Over Time in Breast-Cancer-Specific Mortality in Germany. Dtsch Arztebl Int 2021; 118: 31-32
• 8 Weigel S, Gerss J, Hense HW. et al. Digital breast tomosynthesis plus synthesised images versus standard full-field digital mammography in population-based screening (TOSYMA): Protocol of a randomised controlled trial. BMJ Open 2018; 08: e020475
• 9 Heindel W, Weigel S, Gerß J. et al. TOSYMA Screening Trial Study Group. Digital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): a multicentre, open-label, randomised, controlled, superiority trial. Lancet Oncol 2022; 12